Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| International Society for Gastrointestinal Hereditary Tumours |
RCV000075091 | SCV000106084 | likely pathogenic | Lynch syndrome | 2019-06-21 | reviewed by expert panel | curation | Interrupts canonical donor splice site |
| Ambry Genetics | RCV003162481 | SCV003858897 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2022-12-15 | criteria provided, single submitter | clinical testing | The c.1039-2A>T intronic variant results from an A to T substitution two nucleotides upstream from coding exon 12 in the MLH1 gene. This variant has been identified in a proband whose Lynch syndrome-associated tumor demonstrated high microsatellite instability and loss of MLH1/PMS2 expression by immunohistochemistry (Morak M et al. Eur J Hum Genet, 2019 Dec;27:1808-1820). External RNA studies have demonstrated that this alteration results in an incomplete splice defect; postulated to be due to nonsense-mediated mRNA-decay (Morak M et al. Eur J Hum Genet, 2019 Dec;27:1808-1820). This nucleotide position is highly conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Based on the majority of available evidence to date, this variant is likely to be pathogenic. |